The seasonal influenza A has entered the epidemic period, and the sales of related Chinese Patent Medicine products have significantly increased.

① Recently, the positive rate of influenza virus has significantly increased, with over 99% being type A influenza. Market data shows a clear increase in the demand for various Traditional Chinese Medicine cold medicine products. ② Today, stock prices of several listed companies in the Traditional Chinese Medicine Industry, such as Shanxi Zhendong Pharmaceutical, Hainan Huluwa Pharmaceutical Group, and Zhongsheng Pharmaceutical, have reached the daily limit, with the Traditional Chinese Medicine Sector overall rising, and the Traditional Chinese Medicine 50 ETF increasing by 3.21%.

cls.cnJan 6 21:42

The pig industry is undergoing changes! "Cost reduction" has become the key to success or failure. Are publicly listed pig companies experiencing better-than-expected profit improvements?

Under the dual effect of rising Pork prices and falling costs, the profitability of listed pig farming companies is rapidly improving.

Zhitong FinanceDec 11, 2024 21:21

The demand for vitamins has recovered year-on-year. Tianxin Pharmaceutical states that the changes in supply and demand have led to an increase in the price of folic acid | Direct coverage of the earnings conference.

① Yu Xiaobing, general manager of Tianxin Pharmaceutical, said that demand in the vitamin market showed signs of a year-on-year recovery in the second half of this year, and changes in market supply and demand caused folic acid prices to rise; ② Dong Yi, director of Tianxin Pharmaceutical, answered questions about the fund-raising project.

cls.cnDec 3, 2024 17:45

Tasly Pharmaceutical Group: Some products price reduction led to a decline in Q3 gross margin. All parties are actively promoting the trade with China Resources Sanjiu Medical & Pharmaceutical | Focus on earnings conference

① Affected by the overall low prosperity of the pharmacy industry, the company's pharmaceutical commerce sector saw a decline in revenue in the third quarter this year; the pharmaceutical industry sector's revenue grew year-on-year, but price reductions on some products led to a decrease in gross margin, and the company expects the gross margin to remain stable in the future. ② Regarding the equity trade matters between the company's major shareholder and china resources sanjiu medical & pharmaceutical, the company's general manager Cai Jinyong stated that the company and relevant parties are actively promoting various works for this transaction.

cls.cnNov 27, 2024 22:29

A-share dividends set a new record! List of top stocks in terms of dividend per share in the third quarter.

1. The data shows that the number and total amount of cash dividends proposed in the third quarter reports of A-share listed companies in Shanghai and Shenzhen in 2024 have both reached historical highs; 2. G-bits ranks first in the third quarter dividend list with a dividend of 2 yuan per share, leading the list of stocks with dividend per share in the third quarter (see table).

cls.cnNov 17, 2024 13:10

Hubei Guangji Pharmaceutical was investigated by the CSRC for disclosure violations and was warned in November last year. | Quick read announcement

Tonight, hubei guangji pharmaceutical announced that it is under investigation by the China Securities Regulatory Commission for suspected violations of disclosure regulations; In May of this year, hubei guangji pharmaceutical experienced a wave of rising market trends; Currently, hubei guangji pharmaceutical is deeply trapped in poor performance.

cls.cnOct 25, 2024 19:25